Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies

被引：0

作者：

Rubin, David T. ^{[1
]}

Wolf, Douglas C. ^{[2
]}

Alekseeva, Olga ^{[3
]}

Charles, Lorna ^{[4
]}

Afsari, Sonia ^{[4
]}

Petersen, Ann Katrin ^{[5
]}

Sheffield, James ^{[4
]}

Li, Hongjuan ^{[4
]}

Silva, Diego ^{[4
]}

Lublin, Fred D. ^{[6
]}

Cree, Bruce ^{[7
]}

Cohen, Jeffrey ^{[8
]}

Danese, Silvio ^{[9
]}

机构：

[1] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA

[2] Atlanta Gastroenterol Associates, Ctr Crohns Dis & Ulcerat Colitis, Atlanta, GA USA

[3] Nizhni Novgorod Reg Clin Hosp, Nizhnii Novgorod, Nizhegorod, Russia

[4] Bristol Myers Squibb, Princeton, NJ USA

[5] Bristol Myers Squibb, Princeton, CA USA

[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[7] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA

[8] Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH USA

[9] Humanitas Clin & Res Ctr IRCCS & Hunimed, Ctr Inflammatory Bowel Dis, Milan, Lombardia, Italy

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S853

引用

页码：S396 / S396

页数：1

共 50 条

[31] Long-Term Safety and Efficacy of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the PURSUIT-SC Maintenance Study Extension
Gibson, Peter R.
Reinisch, Walter
Sandborn, William
Feagan, Brian G.
Marano, Colleen W.
Strauss, Richard
Johanns, Jewel
Zhang, Hongyan
Padgett, Lakshmi
Colombel, Jean-Frederic
Collins, Judith
Rutgeerts, Paul J.
GASTROENTEROLOGY, 2014, 146 (05) : S587 - S587
[32] Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension
Reinisch, W.
Gibson, P.
Sandborn, W. J.
Feagan, B. G.
Marano, C.
Strauss, R.
Johanns, J.
Zhang, H.
Padgett, L.
Colombel, J. -F.
Collins, J.
Rutgeerts, P.
JOURNAL OF CROHNS & COLITIS, 2014, 8 : S6 - S7
[33] Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension
Reinisch, Walter
Gibson, Peter R.
Sandborn, William J.
Feagan, Brian G.
Strauss, Richard
Johanns, Jewel
Padgett, Lakshmi
Adedokun, Omoniyi J.
Colombel, Jean-Frederic
Collins, Judith
Rutgeerts, Paul
Tarabar, Dino
Marano, Colleen
JOURNAL OF CROHNS & COLITIS, 2018, 12 (09): : 1053 - 1066
[34] Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment
Sands, Bruce E.
Kobayashi, Taku
Wu, Jianmin
Wang, Isabella Yali
Zhu, Baojin
Redondo, Isabel
Peyrin-Biroulet, Laurent
Walsh, Alissa
Magro, Fernando
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1042 - S1043
[35] INCIDENCE OF INFECTIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD AND RELATIONSHIP TO SIGNIFICANT LYMPHOPENIA: RESULTS FROM A POOLED SAFETY ANALYSIS
Rieder, Florian
Wolf, Douglas C.
Charles, Lorna
Kollengode, Kanthi
Hsu, Kate
Patel, Aditya
Ghosh, Subrata
GASTROENTEROLOGY, 2021, 160 (06) : S339 - S340
[36] CLINICAL REMISSION DEMONSTRATED WITH ORAL OZANIMOD IN THE OVERALL POPULATION AND ACROSS MULTIPLE SUBGROUPS OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE TOUCHSTONE TRIAL
Feagan, Brian G.
Sandborn, William J.
D'Haens, Geert R.
Hanauer, Stephen B.
Wolf, Douglas C.
Vermeire, Severine
Ghosh, Subrata
Petersen, AnnKatrin
Hua, Steven
Shan, Kevin
Liu, Jerry
GASTROENTEROLOGY, 2019, 156 (06) : S1103 - S1104
[37] THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Harris, Sarah
Wu, Chun
Li, Yicong
Maddux, Rachel
Hu, Sarah
Petersen, AnnKatrin
GASTROENTEROLOGY, 2022, 162 (07) : S973 - S973
[38] Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial
Feagan, B. G.
Sandborn, W. J.
D'Haens, G.
Hanauer, S.
Wolf, D. C.
Vermeire, S.
Ghosh, S.
Petersen, A.
Hua, S. Y.
Shan, K.
Liu, J.
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S464 - S464
[39] Etrolizumab Population Pharmacokinetics (Pop PK) and Covariate Analysis in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Wei, Xiaohui
Luca, Diana
Wang, Yehong
O'Byrne, Sharon
Erickson, Rich
Davis, John
Tang, Meina
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S496 - S496
[40] Etrolizumab population pharmacokinetics (Pop PK) and covariate analysis in patients with moderately to severely active ulcerative colitis (UC)
Wei, X. T.
Luca, D.
Wang, Y.
O'Byrne, S.
Erickson, R.
Davis, J. D.
Tang, M. T.
JOURNAL OF CROHNS & COLITIS, 2015, 9 : S46 - S47

← 1 2 3 4 5 →